Cargando…

Hypothesis on the Etiology of Skin Complications in Japanese Patients Using Sodium-Glucose Cotransporter 2 Inhibitors

Detalles Bibliográficos
Autor principal:	Suzuki, Yoshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289145/ https://www.ncbi.nlm.nih.gov/pubmed/28179973 http://dx.doi.org/10.14740/jocmr2897w

Ejemplares similares

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis
por: Morita, Hiroyasu, et al.
Publicado: (2022)

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4
por: Koguchi, Ayako, et al.
Publicado: (2017)

The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Perioperative Implication of Sodium-glucose Cotransporter-2 Inhibitor in a Patient Following Major Surgery
por: Vadi, Sonali, et al.
Publicado: (2021)

Author's reply: Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis
por: Konta, Yusuke, et al.
Publicado: (2022)

A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

An Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors
por: Katsuyama, Hisayuki, et al.
Publicado: (2016)

What Properties of Sodium-Glucose Cotransporter 2 Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight?
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

Sodium/Glucose Cotransporter 2 Inhibition and Urolithiasis: The Effect of Urinary pH and Citrate
por: Harmacek, Dusan, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
por: Peters, R. J. G.
Publicado: (2021)

Prescribing Patterns for Sodium-Glucose Cotransporter 2 Inhibitors: A Survey of Nephrologists
por: Singh, Tripti, et al.
Publicado: (2023)

Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium–glucose cotransporter 2 inhibitors and corticosteroids
por: Nawata, Takashi, et al.
Publicado: (2021)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys
por: Sano, Motoaki, et al.
Publicado: (2016)

Metabolic ketoacidosis with normal blood glucose: A rare complication of sodium–glucose cotransporter 2 inhibitors
por: Ullah, Saad, et al.
Publicado: (2016)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
por: Botana, Manuel, et al.
Publicado: (2022)

Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types
por: Tummalapalli, Sri Lekha, et al.
Publicado: (2021)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitor Use in Acute Heart Failure Hospitalizations Complicated by AKI
por: Aklilu, Abinet M., et al.
Publicado: (2023)

Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor
por: Konta, Yusuke, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Periprocedural Euglycemic Diabetic Ketoacidosis Associated With Sodium–Glucose Cotransporter 2 Inhibitor Therapy During Colonoscopy
por: Meyer, Emily J., et al.
Publicado: (2020)

Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
por: Cho, Eun Hyung, et al.
Publicado: (2018)

Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
por: Zhang, Enxiang, et al.
Publicado: (2021)

Smiling in the New Born Infant - Clinical Observation and Hypothesis about Etiology
por: Nagaraj, S.
Publicado: (1985)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
por: Sasaki, Takashi
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_po7epi68vfu5sbs36jdl5g4kt8